Literature DB >> 26588445

Guidelines for laboratory diagnosis of factor XIII deficiency.

Akbar Dorgalaleh1, Shadi Tabibian, Soudabeh Hosseini, Morteza Shamsizadeh.   

Abstract

Factor XIII (FXIII) deficiency is an extremely rare hemorrhagic disorder with an approximate worldwide incidence of one per two million. With current tests, diagnosis of this disease can be made more precisely. However, factors such as the number of patients with FXIII deficiency (FXIIID), available diagnostic coagulation tests and the number of molecular studies have affected the diagnosis of FXIIID in different parts of the world. Various laboratory approaches can be used, including screening and diagnosis of the disorder in countries with a relatively high rate of FXIIID and recurrent mutation(s) with a simple polymerase chain reaction-restriction fragment length polymorphism analysis or polymerase chain reaction-sequencing for detection of one or a few specific mutations. In other countries, two different laboratory approaches can be used, depending on available coagulation tests. In less-equipped coagulation laboratories, the clot solubility test remains the only diagnostic test for FXIIID. Even in these countries, at least one referral laboratory should perform FXIII activity and, if possible, confirmation of FXIIID by molecular analysis. In countries with well equipped coagulation laboratories, FXIII activity should be used to screen suspected FXIIID patients; more specific tests such as molecular analysis should be used for confirmation. This study suggests a simple, reliable and flexible algorithm for early diagnosis of FXIIID, and may, with one-time diagnosis of FXIIID, reduce the rate of morbidity and mortality in patients with the disorder.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26588445     DOI: 10.1097/MBC.0000000000000459

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  4 in total

1.  Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.

Authors:  Akbar Dorgalaleh; Shadi Tabibian; Mahmood Shams; Behnaz Tavasoli; Maryam Gheidishahran; Morteza Shamsizadeh
Journal:  Lab Med       Date:  2016-06-26

Review 2.  How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.

Authors:  Hojat Shahraki; Akbar Dorgalaleh; Majid Fathi; Shadi Tabibian; Shahram Teimourian; Hasan Mollanoori; Alireza Khiabani; Farhad Zaker
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

3.  Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.

Authors:  Nizar Abdel-Samad
Journal:  Am J Case Rep       Date:  2017-04-22

Review 4.  The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.

Authors:  Christian Kleber; Armin Sablotzki; Sebastian Casu; Martin Olivieri; Kai-Martin Thoms; Johannes Horter; Felix C F Schmitt; Ingvild Birschmann; Dietmar Fries; Marc Maegele; Herbert Schöchl; Michaela Wilhelmi
Journal:  Crit Care       Date:  2022-03-24       Impact factor: 19.334

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.